Skip to main content
ISTH 2024 Main banner
Back

Zhenguo Zhai, MD,PhD

professor
China-Japan Friendship Hospital, Beijing, China; National Clinical Research Center for Respiratory Diseases, Beijing, China
Beijing, Beijing, China (People's Republic)

Dr Zhenguo Zhai, board certified in Pulmonary and Critical Care medicine, now works in Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China.
In his research, he has actively participated clinical and translational studies about genetic polymorphisms studies of pulmonary embolism, inherited mechanisms of the development of pulmonary embolism and chronic thromboembolic pulmonary hypertension, cardiopulmonary function and biomarker response of pulmonary hypertension and thromboembolic pulmonary hypertension, randomized Clinical trials of thrombolytic and anticoagulant therapy of thromboembolic diseases.
As a core member, Dr. Zhai has actively participated several clinical and translational studies and organized the Coopetative Network System for pulmonary vascular diseases. The epidemiological data of pulmonary embolism in China and the baseline data of VTE prevention were obtained. Research interests are in management of venous thromboembolism, acute and longer-term management of pulmonary embolism and pulmonary hypertension. His team is committed to the National Programme for Prevention and Management of Pulmonary Embolism and Deep Venous Thrombosis. The research team showed that low dose rt-PA regimen for acute PE patients with unstable hemodynamic state and/or massive pulmonary artery obstruction, can reduce risk of bleeding but maintain similar efficacy in these patients.

Presentation(s):